Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases

E Miyawaki, H Kenmotsu, K Mori, H Harada… - International Journal of …, 2019 - Elsevier
Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …
被引用次数：44 相关文章

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.

E Miyawaki, H Kenmotsu, K Mori, H Harada… - … Journal of Radiation …, 2019 - europepmc.org
Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases

E Miyawaki, H Kenmotsu, K Mori… - … journal of radiation …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases

E Miyawaki, H Kenmotsu, K Mori, H Harada… - International Journal of …, 2019 - redjournal.org
Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …